Key facts
- This page summarizes Kapil Dhingra's Form 3 filing for LAVA Therapeutics NV (LVTX).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 02 Jan 2025, 09:26.
Kapil Dhingra - 01 Jan 2025 Form 3 Insider Report for LAVA Therapeutics NV (LVTX)
- Reporting relationship
- Director
- Issuer ticker
- LVTX
- Reported as of
- 01 Jan 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 02 Jan 2025, 09:26:47 UTC
- Prior SEC filing
- 06 Jun 2024
- Next SEC filing
- 18 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy Garabedian, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kapil Dhingra filed Form 3 for LAVA Therapeutics NV (LVTX) on 02 Jan 2025.
Change
- Previous filing in this sequence was filed on 06 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LVTX
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 30,000
- Date
- 01 Jan 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LVTX
holding
Derivative
Share Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 104,754
- Exercise price
- $8.14
- Footnotes
- F1, F2
LVTX
holding
Derivative
Share Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 102,986
- Exercise price
- $8.14
- Footnotes
- F2, F3
LVTX
holding
Derivative
Share Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 20,000
- Exercise price
- $5.10
- Footnotes
- F4
LVTX
holding
Derivative
Share Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 20,000
- Exercise price
- $3.64
- Footnotes
- F4
LVTX
holding
Derivative
Share Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 33,390
- Exercise price
- $1.59
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The shares underlying the option vest in 48 equal monthly installments beginning on February 26, 2021, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
Footnote F2
Converted to U.S. dollars based on an exchange rate of 1.00 euro = $1.0389 (rounded to the nearest whole cent), the foreign exchange reference rate on December 31, 2024 as reported by the European Central Bank. Each option may be exercised for a price of 7.84 euros per share.
Footnote F3
The shares underlying the option vest in 48 equal monthly installments beginning on March 17, 2021, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
Footnote F4
Fully vested and immediately exercisable.
Footnote F5
100% of the shares underlying the option will vest on January 19, 2025, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date.